



- PRESS RELEASE -  
For immediate release

## First patient treated with anti-CD39 mAb IPH5201 on OREGA's 10-year anniversary day

**Lyon, France, March 10<sup>th</sup>, 2020** - OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today that the first patient has been treated with the anti-CD39 humanized monoclonal antibody IPH5201. As chance would have it, it happened exactly 10 years to the day of inception of OREGA Biotech.

*"March 9<sup>th</sup> 2020 is marked special for us since our company was celebrating its 10<sup>th</sup> anniversary! In 10 years, we have come a long way and we have succeeded in the model we have chosen: that of discovering new targets and together with our partners bringing them to the patients. And on this 10-year anniversary day the first patient has been dosed with IPH5201, the anti-CD39 monoclonal antibody that we developed in collaboration with Innate Pharma. A nice wink and real pride.",* said Jeremy Bastid, Chief Operating Officer of OREGA Biotech.

### **About IPH5201 and NCT04261075 clinical trial**

IPH5201 is now being developed by Innate Pharma in collaboration with AstraZeneca (AZ). The multicenter, open-label, dose-escalation Phase I study (NCT04261075) will evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of IPH5201 alone, or in combination with AZ's anti-PDL1 monoclonal antibody, durvalumab, with or without AZ's anti-CD73 monoclonal antibody, oleclumab. [More information on the Phase I clinical trial is accessible online.](#)

### **About OREGA Biotech**

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. A new program is underway on a novel potent regulator of anti-PD1 therapy response in anti-PD1 refractory syngeneic mouse models.

Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license



agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.

### **Contact**

Jeremy Bastid, Chief Operating Officer  
Tel.: +33 (0)4 37 49 87 20  
[jeremy.bastid@orega-biotech.com](mailto:jeremy.bastid@orega-biotech.com)

For more information: [www.orega-biotech.com](http://www.orega-biotech.com)